A detailed history of Los Angeles Capital Management LLC transactions in Protagonist Therapeutics, Inc stock. As of the latest transaction made, Los Angeles Capital Management LLC holds 22,446 shares of PTGX stock, worth $934,875. This represents 0.0% of its overall portfolio holdings.

Number of Shares
22,446
Previous 30,827 27.19%
Holding current value
$934,875
Previous $1.07 Million 5.62%
% of portfolio
0.0%
Previous 0.0%

Shares

12 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 04, 2024

SELL
$33.72 - $47.33 $282,607 - $396,672
-8,381 Reduced 27.19%
22,446 $1.01 Million
Q1 2024

Apr 05, 2024

BUY
$21.79 - $32.15 $472,254 - $696,786
21,673 Added 236.76%
30,827 $891,000
Q4 2023

Feb 06, 2024

BUY
$14.05 - $23.44 $128,613 - $214,569
9,154 New
9,154 $209,000
Q2 2023

Aug 03, 2023

SELL
$18.02 - $29.36 $650,648 - $1.06 Million
-36,107 Reduced 79.4%
9,366 $258,000
Q1 2023

May 04, 2023

SELL
$10.78 - $25.38 $339,753 - $799,901
-31,517 Reduced 40.94%
45,473 $1.05 Million
Q3 2022

Nov 02, 2022

BUY
$7.86 - $11.71 $47,631 - $70,962
6,060 Added 8.54%
76,990 $649,000
Q2 2022

Aug 05, 2022

BUY
$7.06 - $25.52 $500,765 - $1.81 Million
70,930 New
70,930 $561,000
Q2 2021

Aug 05, 2021

SELL
$25.57 - $44.88 $1.21 Million - $2.13 Million
-47,387 Closed
0 $0
Q1 2021

May 05, 2021

SELL
$19.02 - $31.15 $11,792 - $19,313
-620 Reduced 1.29%
47,387 $1.23 Million
Q4 2020

Feb 04, 2021

BUY
$18.49 - $25.13 $24,036 - $32,669
1,300 Added 2.78%
48,007 $968,000
Q2 2020

Aug 05, 2020

BUY
$6.19 - $18.84 $108,882 - $331,395
17,590 Added 60.41%
46,707 $824,000
Q1 2020

May 04, 2020

BUY
$5.4 - $9.22 $157,231 - $268,458
29,117 New
29,117 $206,000

Others Institutions Holding PTGX

About Protagonist Therapeutics, Inc


  • Ticker PTGX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 49,084,100
  • Market Cap $2.04B
  • Description
  • Protagonist Therapeutics, Inc., a biopharmaceutical company, discovers and develops peptide-based therapeutic drugs to address hematology and blood disorders, and inflammatory and immunomodulatory diseases. It is developing rusfertide (PTG-300), an injectable hepcidin mimetic that is in Phase II clinical trials for the treatment of patients with...
More about PTGX
Track This Portfolio

Track Los Angeles Capital Management LLC Portfolio

Follow Los Angeles Capital Management LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Los Angeles Capital Management LLC, based on Form 13F filings with the SEC.

News

Stay updated on Los Angeles Capital Management LLC with notifications on news.